Stay Informed. Stay Competitive with FREE Insights on the Stock Market, Dow 30 & Emerging Opportunities. Get Free Email Updates

Stay Competitive With Stock Market Updates!

Get Free Updates

Will The Coronavirus Infect Every Human On The Planet? Atossa’s CEO Says…

By John F. Heerdink, Jr.

In a recent article published at Best Life Online, Steven Quay M.D., Ph.D., the founder of Seattle-based Atossa Therapeutics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and COVID-19 therapeutics, stated “coronavirus won’t stop infecting humans for at least the next decade or so. SARS came with great rapidity and with a lethal rate much higher than SARS-CoV-2, caused about 8,000 cases, and then has apparently disappeared. But with the high rate of both mild cases and asymptomatic patients in SARS-CoV-2, combined with virus shedding documented from the first day of infection and for as much as a month, I predict this coronavirus will infect every human on the planet in the next three years.” 

Steven Quay received his M.D. and Ph.D. from The University of Michigan was a postdoctoral fellow in the Chemistry Department at MIT with Nobel Laureate H. Gobind Khorana, and a resident at the Harvard-MGH Hospital, and spent almost a decade on the faculty of Stanford University School of Medicine. His contributions to medicine have been cited over 9,600 times. He has founded six startups, invented seven FDA-approved pharmaceuticals, and holds 87 US patents. Over 80 million people have benefited from the medicines he invented. His current passions are big medical problems: stopping the COVID-19 pandemic and preventing the two million breast cancers in the world each year. 

Dr. Quay’s company Atossa Therapeutics, Inc. (Nasdaq: ATOS), announced on Thursday, May 28th that it has begun the development of a second COVID-19 program using its proprietary drug candidate AT-301, to be administered by nasal spray. AT-301 is Atossa’s proprietary formula intended for nasal administration in patients immediately following a diagnosis of COVID-19 but who have not yet exhibited symptoms severe enough to require hospitalization. It is intended for at-home use to proactively reduce symptoms of COVID-19 and to slow the infection rate so that a person’s immune system can more effectively fight SARS-CoV-2 (coronavirus). Atossa also intends to conduct testing to determine whether AT-301 can be used as a prophylaxis to prevent or mitigate SARS-CoV-2, with the goal that it could become a “bridge to the vaccine” and be useful in the next phase of the coronavirus pandemic.

“In April we launched our AT-H201 COVID-19 HOPE program for the most severely ill COVID-19 patients. By contrast, our new AT-301 nasal spray program is being developed for the relatively healthier COVID-19 patients who have not been hospitalized. We are developing AT-301 with a nasal spray delivery mechanism because many COVID-19 patients are infected via the nasal passage. The mechanism of action is intended to inhibit essential human host proteases, which are found in abundance in the nasal mucosa, from activating the SARS-CoV-2 Spike Protein, the known first and obligatory step that must be taken before the virus can enter the body. This may eventually be useful as a prophylactic, to be used before leaving the home. In that setting, it would be intended to create a barrier inside the nose to prevent virus entry – sort of a short-term vaccine-like treatment that could be helpful before a true vaccine is available. Our goal with the two COVID-19 programs is to ultimately commercialize therapies for patients on both ends of the spectrum – from the healthier patients who will be treated at home and the sicker patients who require mechanical ventilation in the hospital,” stated Steven Quay, M.D., Ph.D., President, and CEO of Atossa.
Atossa has retained Summit Biosciences, Inc., a pharmaceutical company with a proven track record in nasal spray medicines, to develop and produce a clinical supply of pre-filled nasal spray products in multi-dose devices containing AT-301 with the goal of commencing initial human clinical trials in the third quarter 2020. Founded in 2009, Summit Biosciences, Inc. of Lexington, KY ( is a privately-held, specialized pharmaceutical company focused on developing, manufacturing, and commercializing generic and innovative nasal spray medicines. It collaborates on the development of products with its clients and manufactures them at an industrial scale primarily for commercialization in the US and Europe.


The next steps with this program include the design and manufacturing of the clinical trial materials and the active pharmaceutical ingredients in AT-301 followed by adequate and well-controlled studies to demonstrate safety and efficacy. These studies must be successfully completed and regulatory approvals must be obtained before AT-301 may be commercialized. Atossa has filed provisional patent applications on AT-301 to treat patients diagnosed with, or to prevent, COVID-19 via nasal spray and intends to apply to the FDA as soon as possible so that human clinical trials may be commenced in the third quarter 2020.


Atossa’s shares have been on an upward trend lately after touching a low of $.76/share during the recent market selloff but today are currently trading in the $2.63/share range. The 52-week high is $3.25.


Maxim Group’s Sell-side Biotech Analyst Jason McCarthy issued an update report today on Atossa Therapeutics, Inc. (NASDAQ: ATOS) titled “Expanding into the COVID-19 Therapeutics Race with a Differentiated Approach – Reiterate Buy.” He maintains a Buy Rating with a $4/share 12-month price target. View Maxim’s report here.


Receive Vista Partner’s FREE updates to your email box by signing up in seconds here!

Please visit the Atossa Therapeutics (ATOS) page at Vista Partners to keep up with their progress and to learn more daily about their work and developments.


Dr. Quay is also working on a secret project that gives you coveted life-saving tips.

It’s called Your COVID-19 Survival Manual: A Physician’s Guide to Keep You and Your Family Healthy during the Pandemic and Beyond

In it, he gives you:

✔ One 2-minute step you can take every time you come home to kill Coronavirus before it enters your lungs.

✔ A quick, free home test for COVID-19 that is as good as the FDA-approved nasal swab.

✔ The one exercise you won’t learn in the gym that can save your life.

✔ How NOT to die of COVID-19.

✔ What to do if you have early stage COVID-19, so that you can stay out of the hospital.

✔ The #1 most effective way to prevent the spread of coronavirus as we reopen society (Hint: it’s the one thing the CDC said was “NOT effective” when coronavirus hit the U.S.)

✔ Why a vaccine won’t be the solution, and what YOU can do to protect yourself, now and in the future.

✔ What to eat and drink (and what to avoid) so you can prevent and beat this coronavirus.

✔ The best supplements I have found from clinical trial research for immune health during this pandemic.

✔ A cheap and easy DIY step that takes your face mask from a viral barrier to a virus killer, giving you over 100-times the protection of an untreated mask.

✔ The one blood test to ask for if you are hospitalized that can keep you off a ventilator.

And much, much more.

And for those of you who are curious about the functions and implications of the virus, and for those of you who are planning ahead for the next epidemic, he shares:

  • The coronavirus’ “Diabolic Trait,” how it helped the virus spread so fast, and what you can do to stop it
  • Three steps to take to thrive during the next epidemic
  • What gain-of-function research is, and why we must ban it to prevent future pandemics.

This is only a fraction of the information he will give you.

For all the details, bookmark this link. And be ready to use it Monday when the book goes live.

Post View Count : 69326
(Read Original Story: Will Coronavirus Go Away Without a Vaccine? Here's What Experts Say in Best Life Online)


Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us